Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 14/20 | 0.47 |
| ▸ | THRA | P10827 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111651 | 0.90 | THRA (0.61) | THRBTHRAALDH1A1MMEACE | |
| SCHEMBL5108855 | 0.90 | THRB (0.47) | THRBTHRAALDH1A1MMEACE | |
| SCHEMBL5111579 | 0.89 | ALDH1A1 (0.46) | THRBTHRAALDH1A1MMEACE | |
| SCHEMBL5116916 | 0.88 | THRB (0.50) | THRBTHRAALDH1A1LMNA | |
| SCHEMBL4930845 | 0.87 | THRB (0.49) | THRBTHRAMMEACECPA1 | |
| SCHEMBL5107973 | 0.87 | THRA (0.43) | THRBTHRAALDH1A1MMEACE | |
| SCHEMBL5722591 | 0.87 | THRB (0.41) | THRBTHRAALDH1A1SMN1; SMN2 | |
| SCHEMBL5115594 | 0.86 | THRB (0.50) | THRBTHRAALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5111550 | 0.86 | THRB (0.50) | THRBTHRAALDH1A1 | |
| SCHEMBL4922875 | 0.86 | THRB (0.52) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1732532-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092316-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885ALDH1A1 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.